Crescent Biopharma, Inc. (CBIO) — Cash Flow-to-Debt Ratio
Crescent Biopharma, Inc. (CBIO) has a Cash Flow-to-Debt Ratio of -1.00x as of June 2026, meaning its operating cash flow of $-19.46 Million could theoretically repay -1% of its total liabilities ($19.50 Million) in one year. See CBIO free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Crescent Biopharma, Inc. Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Crescent Biopharma, Inc. across 15 annual periods. For the full cash flow conversion analysis, see Crescent Biopharma, Inc. operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Crescent Biopharma, Inc. (2011–2025)
Year-by-year debt coverage analysis for Crescent Biopharma, Inc.. Check Crescent Biopharma, Inc. (CBIO) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.92x | $-71.53 Million | $37.28 Million | ▼ -215.3% |
| 2024 | -0.61x | $-31.10 Million | $51.10 Million | ▲ +88.0% |
| 2023 | -5.05x | $-34.88 Million | $6.90 Million | ▲ +3.4% |
| 2022 | -5.23x | $-46.46 Million | $8.88 Million | ▼ -16.0% |
| 2021 | -4.51x | $-57.49 Million | $12.74 Million | ▼ -68.0% |
| 2020 | -2.69x | $-39.24 Million | $14.61 Million | ▲ +28.9% |
| 2019 | -3.78x | $-51.98 Million | $13.77 Million | ▲ +18.3% |
| 2018 | -4.62x | $-43.33 Million | $9.38 Million | ▼ -37.9% |
| 2017 | -3.35x | $-29.77 Million | $8.88 Million | ▲ +20.1% |
| 2016 | -4.20x | $-29.73 Million | $7.09 Million | ▼ -306.7% |
| 2015 | -1.03x | $-8.24 Million | $7.99 Million | ▼ -55.6% |
| 2014 | -0.66x | $-4.28 Million | $6.46 Million | ▲ +89.9% |
| 2013 | -6.54x | $-15.54 Million | $2.38 Million | ▼ -267.9% |
| 2012 | -1.78x | $-10.47 Million | $5.89 Million | ▼ -362.5% |
| 2011 | 0.68x | $13.85 Million | $20.45 Million | — |